Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind and Placebo-controlled Phase III Trial Comparing Fruquintinib Efficacy and Safety vs Best Support Care (BSC) in Advanced Colorectal Cancer Patients Who Have Failed at Least Second Lines of Chemotherapies

Trial Profile

A Randomized, Double-blind and Placebo-controlled Phase III Trial Comparing Fruquintinib Efficacy and Safety vs Best Support Care (BSC) in Advanced Colorectal Cancer Patients Who Have Failed at Least Second Lines of Chemotherapies

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 10 Nov 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fruquintinib (Primary)
  • Indications Colorectal cancer; Liver metastases
  • Focus Registrational; Therapeutic Use
  • Acronyms FRESCO
  • Sponsors Hutchison MediPharma
  • Most Recent Events

    • 09 Nov 2023 According to a HUTCHMED media release, Takeda received approval from the U.S. Food and Drug Administration ("FDA") for FRUZAQLA™ (fruquintinib), ) for previously treated metastatic colorectal cancer, based on data from FRESCO-2 and FRESCO trials.
    • 15 Jun 2023 According to a Takeda media release, the European Medicines Agency (EMA) has validated and accepted for regulatory review the marketing authorization application (MAA) for fruquintinib, for the treatment of adult patients with previously treated metastatic colorectal cancer (CRC). The MAA for fruquintinib includes results FRESCO-2 and FRESCO trials.
    • 25 May 2023 According to a Takeda media release, U.S. Food and Drug Administration (FDA) has granted priority review of the New Drug Application (NDA) for fruquintinib based on the results of FRESCO and FRESCO-2 studies. The Prescription Drug User Fee Act (PDUFA) goal date assigned by the FDA for this NDA is November 30, 2023.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top